, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.

Montine TJ, Markesbery WR, Morrow JD, Roberts LJ
Ann Neurol. 1998 44 (3): 410-3

PMID: 9749613 · DOI:10.1002/ana.410440322

Postmortem studies have associated Alzheimer's disease (AD) with regionally increased oxidative damage to brain. Lacking, however, is a specific marker of oxidative damage to brain that may be measured during life. We tested the hypothesis that cerebrospinal fluid (CSF) concentrations of F2-isoprostanes (F2-IsoPs), stable products of arachidonate peroxidation, are increased in CSF of AD patients. CSF from lateral ventricles (VF) was analyzed from 11 AD patients and 11 control subjects who participated in a rapid autopsy program. VF F2-IsoP concentrations were significantly elevated in AD patients compared with control subjects (72 +/- 7 vs 46 +/- 4 pg/ml) and were significantly linearly correlated with brain weight (-0.3 pg/ml/g, r2 = 0.32). These results suggest that quantification of CSF F2-IsoP concentrations may provide a useful biomarker of central nervous system oxidative damage in AD.

MeSH Terms (8)

Aged Aged, 80 and over Alzheimer Disease Biomarkers Dinoprost Female Humans Male

Connections (1)

This publication is referenced by other Labnodes entities: